Lonza Group AG
Sector and Industry
Healthcare, Healthcare Services
Performance (1Y)
11.83%
Market Cap
37.06 Bil.
P/E Ratio
0.00
Dividend Yield
0.93 %
Earnings per Share
-4.20 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| UnitedHealth Group Inc. | 254.66 Bil. | 396.73 Bil. | 24.94 | -19.75 % | 0.00 | - |
| Thermo Fisher Scientific Inc. | 185.62 Bil. | 39.50 Bil. | 32.67 | +1.45 % | 0.00 | - |
| Danaher Corp. | 137.79 Bil. | 21.78 Bil. | 45.36 | -11.47 % | 0.00 | - |
| McKesson Corporation | 90.13 Bil. | 348.09 Bil. | 22.55 | +33.83 % | 0.00 | - |
| HCA Healthcare Inc. | 89.28 Bil. | 67.01 Bil. | 16.48 | +12.93 % | 0.00 | - |
| Elevance Health Inc. | 65.88 Bil. | 176.51 Bil. | 13.91 | -9.22 % | 0.00 | - |
| The Cigna Group | 61.74 Bil. | 243.65 Bil. | 12.41 | +66.33 % | 0.00 | - |
| Cencora Inc. | 51.58 Bil. | 291.15 Bil. | 39.26 | +1.16 % | 0.00 | - |
| IDEXX Laboratories Inc. | 45.92 Bil. | 3.81 Bil. | 51.74 | +14.41 % | 0.00 | - |
| Zoetis Inc. | 45.52 Bil. | 8.39 Bil. | 20.89 | +3.10 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 528 G | 0 Units |
| PRICE DETERMINATION TIME | 06/04/2026 / 09:05:15 AM | |
| DAILY VOLUME (UNITS) | 0 | |
| DAILY HIGH / LOW | 531.8 | 525 |
| PREV. DAY'S PRICE | 530.6 | (06/03) |
| CHANGE DAY BEFORE | -2.60 | -0.49 % |
| 52 WEEK HIGH / LOW | 633.6 (10/27) | 499.1 (03/23) |
Key Figures (in EUR)
| 2027e | 2026e | 2025 | 2024 | 2023 | |
|---|---|---|---|---|---|
| EARNINGS PER SHARE | 23.58 | 19.88 | -4.20 | 9.39 | 9.15 |
| DIVIDENDS PER SHARE | 7.13 | 6.03 | 5.35 | 4.20 | 4.12 |
| DIVIDEND YIELD IN % | - | - | 0.93 % | 0.75 % | 1.13 % |
| DIVIDEND GROWTH IN % | - | - | 27.28 % | 2.00 % | 18.07 % |
| PRICE - EARNINGS RATIO | 23.27 | 27.60 | 35.78(e) | 59.96 | 39.82 |
| PRICE - BOOK RATIO | - | - | 4.75 | 4.06 | 2.70 |
| PRICE - SALES RATIO | - | - | 5.77 | 5.81 | 3.88 |
| PRICE - CASH FLOW RATIO | - | - | 32.21 | 29.18 | 18.37 |
Master Data
| WKN | 928619 |
| ISIN | CH0013841017 |
| SYMBOL | - |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | Lonza Group |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | Swiss Franc |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Healthcare Services |
| NUMBER OF SHARES | 69.84 Mil. |
| MARKET CAPITALISATION | 37.06 Bil. |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | -2.10 % | 1.41 % | -7.88 % | -10.43 % | -11.83 % | - | - | -7.46 % |
| HIGH | 555.40 | 555.40 | 590.80 | 628.20 | 633.60 | - | - | 628.20 |
| LOW | 529.80 | 505.40 | 499.10 | 499.10 | 499.10 | - | - | 499.10 |
Dividend
per share
Company profile
Lonza Group AG engages in the supply of pharmaceutical, healthcare, and life science products. It operates through the following segments: Biologics, Small Molecules, Cell and Gene, Capsule and Health Ingredients, and Corporate. The Biologics segment serves as contract development and manufacturing partner for biopharmaceuticals, catering customers for all clinical and commercial manufacturing needs throughout the product lifecycle. The Small Molecules segment design, development, and manufacturing, with the ability to offer integrated drug substances to drug product solutions, including particle engineering and drug product packaging. The Cell and Gene segment develops, de-risk, commercializes, and scales their emerging therapies through its three business areas Cell and Gene Technologies, Bioscience, and Personalized Medicine. The Capsule and Health Ingredients segment provides innovative capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical companies. The Corporate segment refers to finance and accounting, legal, communication, information technology, and human resources functions. The company was founded on October 27, 1897 and is headquartered in Basel, Switzerland.
Structured products for Lonza Group AG
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
No company events available.